ValiRx plc (GB:VAL) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ValiRx PLC has extended its exclusivity agreement with TheoremRx Inc until the end of 2024, in exchange for a 0.5% equity stake. This extension aims to support TheoremRx in securing financing necessary for the sublicensing of ValiRx’s VAL201 cancer therapeutic. Investors are watching closely as the deal remains non-binding and dependent on successful financial arrangements.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.